Consensus Evolent Health, Inc.

Equities

EVH

US30050B1017

Market Closed - Nyse Other stock markets 04:00:02 2024-05-10 pm EDT			5-day change	1st Jan Change
24.46 ^USD	-9.27%		-9.74%	-25.95%

May. 10	UBS Trims Price Target on Evolent Health to $44 From $46, Keeps Buy Rating	MT
May. 09	Evolent Health Q1 Adjusted Earnings, Revenue Rise; Q2 Revenue Guidance Set, 2024 Revenue Outlook Increased	MT

Evolution of the average Target Price on Evolent Health, Inc.

Price target over the last 5 years

History of analyst recommendation changes

efd5496f53e24f4c636d4581856d081._vHkq-_8bcuxIGUIUUUqon9l-2XQcWiM3t3hKactBVo.kbuz3LmbXbj3RBdMZxZ52gg9mCLkQi7UuJGyb89MZDeWgJzP34QA_MVZDg~eee3ea50d2477d052a147dfce99bcde8

Analyst Recommendations on Evolent Health, Inc.

UBS Trims Price Target on Evolent Health to $44 From $46, Keeps Buy Rating	May. 10	MT
Citigroup Starts Coverage on Evolent Health With Buy Rating, $40 Price Target	Apr. 22	MT
Canaccord Genuity Trims Price Target on Evolent Health to $44 From $45, Maintains Buy Rating	Mar. 28	MT
JPMorgan Trims Price Target on Evolent Health to $52 From $53, Maintains Overweight Rating	Mar. 15	MT
Canaccord Genuity Cuts Price Target on Evolent Health to $45 From $47, Maintains Buy Rating	Feb. 23	MT
JMP Securities Initiates Evolent Health With Market Outperform Rating, Price Target is $37	Dec. 06	MT
RBC Trims Price Target on Evolent Health to $42 From $44, Keeps Outperform Rating	Nov. 28	MT
Truist Securities Trims Price Target on Evolent Health to $34 From $36, Maintains Hold Rating	Nov. 14	MT
UBS Starts Evolent Health With Buy Rating, Price Target is $46	23-10-16	MT
Guggenheim Adjusts Price Target on Evolent Health to $47 From $50, Maintains Buy Rating	23-06-26	MT
Stephens Initiates Evolent Health at Overweight With $40 Price Target	23-04-12	MT
Cowen Adjusts Price Target on Evolent Health to $59 From $57, Maintains Outperform Rating	23-01-30	MT
Cowen Adjusts Evolent Health's Price Target to $57 From $52, Keeps Outperform Rating	22-11-18	MT
Truist Securities Starts Evolent Health at Hold With $33 Price Target	22-11-01	MT
Canaccord Genuity Cuts Evolent Health's Price Target to $48 From $55, Reiterates Buy Rating	22-10-12	MT
BTIG Trims Evolent Health's Price Target to $45 From $55, Keeps Buy Rating	22-10-12	MT
JPMorgan Adjusts Evolent Health's Price Target to $52 From $37, Reiterates Overweight Rating	22-08-19	MT
RBC Raises Price Target on Evolent Health to $44 From $40, Maintains Outperform Rating	22-08-03	MT
BTIG Adjusts Evolent Health's Price Target to $50 From $45, Reiterates Buy Rating	22-08-03	MT
Piper Sandler Adjusts Evolent Health's Price Target to $40 From $35, Reiterates Overweight Rating	22-08-03	MT
RBC Initiates Evolent Health at Outperform With $40 Price Target, Sees 'Significant Organic Revenue Growth Opportunity'	22-07-29	MT
Cowen Raises Evolent Health's Price Target to $50 From $48, Maintains Outperform Rating	22-06-21	MT
Piper Sandler Adjusts Evolent Health Price Target to $35 From $37, Maintains Overweight Rating	22-05-17	MT
Canaccord Genuity Adjusts Evolent Health's Price Target to $45 from $40, Keeps Buy Rating	22-05-09	MT
Piper Sandler Adjusts Evolent Health's Price Target to $37 From $32, Reiterates Overweight Rating	22-04-25	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.46 USD

Average target price

43.29 USD

Spread / Average Target

+76.97%

High Price Target

63 USD

Spread / Highest target

+157.56%

Low Price Target

34 USD

Spread / Lowest Target

+39.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Evolent Health, Inc.

UBS
Citigroup
Canaccord Genuity
JPMorgan Chase
JMP Securities
RBC Capital Markets
Truist Securities
Guggenheim
Stephens Inc.
Cowen
Goldman Sachs
Piper Sandler
BTIG

Ratings for Evolent Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar